chartexchange

Fujitsu Japan verifies utility of AI and U.S.-based Paradigm platform to streamline clinical trial candidate screening

JCN Newswire | Nov 19, 2026 2:58 AM EST

Fujitsu Japan Limited [1] (Fujitsu Japan), together with the National Cancer Center Hospital East [2] (NCCHE) and U.S.-based Paradigm Health, Inc. [3] (Paradigm), conducted joint research into the use of a Large Language Model (LLM) and Paradigm's clinical trial matching platform, "Paradigm Platform" [4], to support the identification of potential candidates for clinical trials of new drugs.

Read original article